The 2022–2023 ECDC PPS was the third EU-wide point prevalence survey of healthcare-associated infections and antimicrobial use in acute care hospitals.
This protocol describes a survey undertaken to acquire a snapshot of the distribution of Clostridioides difficile strains in tertiary acute care hospitals in the European Union/European Economic Area (EU/EEA) in 2022–2023
In 2019, 8 874 (7.4%) of patients staying in an intensive care unit (ICU) for more than two days presented with at least one ICU-acquired healthcare-associated infection (HAI) under surveillance (pneumonia, bloodstream infection, or urinary tract infection).
The 2016–2017 ECDC point prevalence survey was the second EU-wide point prevalence survey of healthcare-associated infections and antimicrobial use in acute care hospitals.
This report is based on data for 2018-2020 retrieved on 13 February 2023 from The European Surveillance System (TESSy) and ECDC’s decentralised data storage for antimicrobial resistance and healthcare-associated infections (ARHAI). TESSy is a system for the collection, analysis and dissemination of data on communicable diseases.
The laboratories participating in the QA21 EQA scheme for antimicrobial susceptibility testing of N. gonorrhoeae showed good levels of competency and capability in recovering and testing strains of unknown phenotype.
The surveillance of Neisseria gonorrhoeae antimicrobial susceptibility in the European Union/European Economic Area (EU/EEA) is essential for detecting emerging and increasing antimicrobial resistance. Since 2009, this surveillance has been co-ordinated by the European Centre for Disease Prevention and Control (ECDC). The quality-assured data produced can be used to inform treatment guidelines.